{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:23Z","timestamp":1789958843316,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/leu.2016.6","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T04:51:17Z","timestamp":1454475077000},"page":"1606-1609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy"],"prefix":"10.1038","volume":"30","author":[{"given":"Z","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C C","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"BFleu20166_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I et al. Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis. Blood 2012; 120: 761\u2013767.","journal-title":"Blood"},{"key":"BFleu20166_CR2","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, M\u00fcller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760\u20136768.","journal-title":"Blood"},{"key":"BFleu20166_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000046636","volume":"107","author":"B Johansson","year":"2002","unstructured":"Johansson B, Fioretos T, Mitelman F . Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76\u201394.","journal-title":"Acta Haematol"},{"key":"BFleu20166_CR4","doi-asserted-by":"publisher","first-page":"e0129648","DOI":"10.1371\/journal.pone.0129648","volume":"10","author":"W Haa\u00df","year":"2015","unstructured":"Haa\u00df W, Kleiner H, Wei\u00df C, Haferlach C, Schlegelberger B, M\u00fcller MC et al. Clonal evolution and blast crisis correlate with enhanced proteolytic activity of separase in BCR-ABL b3a2 fusion type CML under imatinib therapy. PloS One 2015; 10: e0129648.","journal-title":"PloS One"},{"key":"BFleu20166_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ajh.23887","volume":"90","author":"C Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini C, Piazza R . How I treat newly diagnosed chronic myeloid leukemia in 2015. Am J Hematol 2015; 90: 156\u2013161.","journal-title":"Am J Hematol"},{"key":"BFleu20166_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","volume":"2011","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A . Educational session: Managing chronic myeloid leukemia as a chronic disease. Hematology Am Soc Hematol Educ Program 2011; 2011: 128\u2013135.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu20166_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, M\u00fcller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV. Leukemia 2015; 29: 1123\u20131132.","journal-title":"Leukemia"},{"key":"BFleu20166_CR8","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1007\/s00277-015-2316-0","volume":"94","author":"M Pfirrmann","year":"2015","unstructured":"Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J . Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Ann Hematol 2015; 94: S209\u2013S218.","journal-title":"Ann Hematol"},{"key":"BFleu20166_CR9","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1007\/s00277-015-2324-0","volume":"94","author":"S Saussele","year":"2015","unstructured":"Saussele S, Silver RT . Management of chronic myeloid leukemia in blast crisis. Ann Hematol 2015; 94: S159\u2013S165.","journal-title":"Ann Hematol"},{"key":"BFleu20166_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2174\/138920212802510466","volume":"13","author":"KM Greulich-Bode","year":"2012","unstructured":"Greulich-Bode KM, Heinze B . On the power of additional and complex chromosomal aberrations in CML. Curr Genomics 2012; 13: 471\u2013476.","journal-title":"Curr Genomics"},{"key":"BFleu20166_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cancergencyto.2010.02.003","volume":"199","author":"A Zaccaria","year":"2010","unstructured":"Zaccaria A, Testoni N, Valenti AM, Luatti S, Tonelli M, Marzocchi G et al. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genet Cytogenet 2010; 199: 76\u201380.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFleu20166_CR12","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","volume":"126","author":"W Wang","year":"2015","unstructured":"Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 2015; 126: 1699\u20131706.","journal-title":"Blood"},{"key":"BFleu20166_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R . How I treat CML blast crisis. Blood 2012; 120: 737\u2013747.","journal-title":"Blood"},{"issue":"1","key":"BFleu20166_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","volume":"2007","author":"J. P. Radich","year":"2007","unstructured":"Radich JP . The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program 2007, 384\u2013391.","journal-title":"Hematology"},{"key":"BFleu20166_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","volume":"55","author":"EJ Jabbour","year":"2014","unstructured":"Jabbour EJ, Hughes TP, Cort\u00e9s JE, Kantarjian HM, Hochhaus A . Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 2014; 55: 1451\u20131462.","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu20166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20166","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:42:39Z","timestamp":1781916159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu20166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFleu20166"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]},"assertion":[{"value":"3 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}